- Significance of Protein Aggregation to Therapeutic Protein Products
- Effects of Protein Aggregates: An Immunologic Perspective
- Evaluation of the Immuno-Stimulatory Potential of Stopper Extractables and Leachables by Using Dendritic Cells as Readout
Allergens and Immunogenicity
- CD4+ T cell epitope identification: applications to allergy
- Allergic reactions to drugs: involvement of T cells
Autologous Proteins
- An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma
- Clinical link between MHC class II haplotype and interferon-beta (IFN-h) immunogenicity
- Immunomics: discovering new targets for vaccines and therapeutics
- Immunogenicity of interferon beta: differences among products
- Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoiein
- Human Immune Response to Recombinant Human Proteins
- AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
Complicating Factors
- The expanding realm of heterologous immunity: friend or foe?
- Comparative immunopeptidomics of humans and their pathogens
- Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry?
- Epitope dominance, competition and T cell affinity maturation
Deimmunization Papers
- Immunogenicity issues with therapeutic proteins (Amin, Carter)
- Immunogenicity of Protein Therapeutics (De Groot, Scott)
- Limiting the risk of immunogenicity by identification and removal of T-cell epitopes (DeImmunisationâ„¢)
- Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-Beta Does Not Result in an In Vivo Response Directed at the Subdominant Epitope
- Identification and removal of immunogenicity in therapeutic proteins
- Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity
- Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”
HLA Immunogenicity Link
- Structural and Functional Consequences of Altering a Peptide MHC Anchor Residue
- CD8 and B cell memory: same strategy, same signals
MHC and T Cell Ligand Issues
- Structural and Functional Consequences of Altering a Peptide MHC Anchor Residue
- T Cell Cross-Reactivity and Conformational Changes during TCR Engagement
Methods for Measuring Immunogenicity
- Use of HLA class II tetramers in tracking antigen-specific T cells and mapping T cell epitopes
- Modeling the immonogenicity of therapeutic proteins using T cell epitope mapping
- Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools
- Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires
- Modelling the Immonogenicity of Therapeutic Proteins Using T Cell Epitope Mapping
- Design and Validation of a Non Cell-Based Receptor Binding Assay for the Detection of Neutralizing Antibodies to a Biological Therapeutic
- Determination of Immunogenicity for a humanized monoclonal antibody: Special Considerations
- A Community Resource Benchmarking Predictions of Peptide Binding to MHC-I Molecules
- ProPred1: prediction of promiscuous MHC Class-I binding sites
- Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires
- An In Vitro Human Cell-Based Assay to Rank the Relative Immunogenicity of Proteins
- Methods, Volume 34, Issue 4, Pages 425-501 (December 2004) Bioinformatics in Vaccine Design
- Drug Discovery Tutorial: Epitope Mapping & Therapeutic Proteins
- Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics
Peptide Processing
- Two Human Immunodeficiency Virus Vaccinal Lipopeptides Follow Different Cross-Presentation Pathways in Human Dendritic Cells
- Synthetic insertion signal sequences enhance MHC class I presentation of a peptide from the melanoma antigen MART-1
- Proteases, Proteases and Proteases for Presentation
- An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope
Promiscuous Epitopes
- A continuous central motif of invariant chain peptides, CLIP, is essential for binding to various I-A MHC class II molecule
- Major histocompatibility complex and T cell interactions of a universal T cell epitope from Plasmodium falciparum circumsporozoite protein
- Data for Clustered Promiscuous Epitopes
Proof of Principle
- Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-beta Does Not Result in an In Vivo Response Directed at the Subdominant Epitope
- The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection
Review of Immunogenicity Papers
- T cell Epitope: Friend or Foe? Immunogenicity of biologics in context
- An Overview of Scientific and Regulatory Issues for the Immunogenicity of Biological Products
- Immune Responses to Therapeutic Proteins in Humans - Clinical Significance, Assessment and Prediction
- Delivery of Protein Therapeutics
- Immunogenicity of Biological Therapeutics: A Hierarchy of Concerns
- Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics
T-Regs and Immunogenicity
T and B Cell Epitope Co-Localization
- Identification of B- and T-Cell Epitopes of BB, a Carrier of Protein Derived from the G Protein of Streptococcus Strain G148
- Identification of B- and T-Cell Epitopes within the Fibronectin-Binding Domain of the SfbI Protein of Streptococcus pyogenes
- Recognition of the Immunodominant Myelin Basic Protein Peptide by Autoantibodies and HLA-DR2-restricted T Cell Clones from Multiple Sclerosis Patients
- Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site
Toll-Like Receptors